Havrdova, Eva <br/><br/>
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.  [electronic resource] 

 -  Expert opinion on pharmacotherapy  Oct 2013 
 - 2145-56 p.  digital 
<br/><br/> Publication Type: Journal Article; Comment 
<br/><br/><label>ISSN: </label>1744-7666 
<br/><br/><label>Standard No.: </label>10.1517/14656566.2013.826190  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Female<br/>Fumarates--therapeutic use<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Male<br/>Multiple Sclerosis, Relapsing-Remitting--drug therapy<br/>Peptides--therapeutic use